Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …

Non-alcoholic fatty liver disease (NAFLD) is in parallel with the obesity epidemic and it is the
most common cause of liver diseases. The development of hepatic steatosis in majority of …

Background Several steatosis biomarkers are available with limited independent validation.
Aim To determine diagnostic value and limitations of several steatosis biomarkers using liver …

The Visceral Adiposity Index (VAI) has recently proven to be an indicator of adipose
distribution and function that indirectly expresses cardiometabolic risk. In addition, VAI has …

Obesity and its co-morbidities, including type II diabetes, insulin resistance and
cardiovascular diseases, have become one of the biggest health issues of present times …

Aims Although there is still no clear definition of “adipose tissue dysfunction” or ATD, the
identification of a clinical marker of altered fat distribution and function may provide the …

Background & Aims Non-alcoholic steatohepatitis (NASH) is prevalent in adults with obesity
and can progress to cirrhosis. In a secondary analysis of prospectively acquired data from …

Surrogate indexes of visceral adiposity, a major risk factor for metabolic and cardiovascular
disorders, are routinely used in clinical practice because objective measurements of visceral …

Nonalcoholic fatty liver disease (NAFLD) is associated with visceral obesity. However, the
association between visceral adipose tissue (VAT) area and fibrosis in NAFLD patients has …

Obesity is associated with a major prevalence of cardiovascular risk factors and high risk of
cardiovascular events and contributes to the increase in cardiovascular morbidity and …